Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Large Cell Lymphoma
Interventions
DRUG

SGN-30

Trial Locations (13)

10021

Memorial Sloan-Kettering, New York

21827

Johns Hopkins, Baltimore

35294

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University, Nashville

44106

Cleveland University, Cleveland

55455

University of Minnesota, Minneapolis

60611

Northwestern Universtiy, Chicago

60612

University of Illinois at Chicago, Chicago

77030

MD Anderson Cancer Center, Houston

90095

University of California at Los Angeles, Los Angeles

94305

Stanford University, Stanford

97227

Kaiser Permanente - Oncology Research, Portland

06520

Yale, New Haven

All Listed Sponsors
lead

Seagen Inc.

INDUSTRY

NCT00099255 - Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma | Biotech Hunter | Biotech Hunter